References
- Safian RD, Textor SC. Renal-artery stenosis. New Engl J Med 2001;344:431-42
- Chrysochou C, Kalra PA. Epidemiology and natural history of atherosclerotic renovascular disease. Progr Cardiovasc Dis 2009;52:184-95
- ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953-62
- Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370:13-22
- Yu MS, Folt DA, Drummond CA, et al. Endovascular versus medical therapy for atherosclerotic renovascular disease. Curr Atheroscler Rep 2014;16:459
- Sarac TP. Influence and critique of the ASTRAL and CORAL Trials. Semin Vasc Surg 2011;24:162-6
- Dorros G, Jaff M, Mathiak L, et al. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. Circulation 1998,98:642-7
- Rzeznik D, Przewlocki T, Kablak-Ziembicka A, et al. Effect of renal artery revascularization on left ventricular hypertrophy, diastolic function, blood pressure, and the one-year outcome. J Vasc Surg 2011;53:692-7
- Rundback JH, Sacks D, Kent KC, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc Intervent Radiol 2002;13:959-74
- Parikh SA, Shishehbor MH, Gray BH, et al. SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Intervent 2014;84:1163-71
- Wu JR, Liou SF, Lin SW. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009;59:48-56
- Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guideline on prevention and treatment of dyslipidemia in adults (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:390-419
- Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006;113:657-63
- Peng M, Wu S, Jiang X, et al. Long-term alcohol consumption is an independent risk factor of hypertension development in northern China: evidence from Kailuan study. J Hypertens 2013;31:2342-7
- American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care 2012;35:S11
- Chinese Diabetes Society. Chinese clinical guideline for continuous glucose monitoring (2007). Chinese guideline on prevention and treatment of type 2 diabetes (in Chinese). Chin Med J 2008;88:1227-45
- Burnier M. Renal protection with calcium antagonists: the role of lercanidipine. Curr Med Res Opin 2013;29:1727-35
- Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
- Shepherd J, Kastelein JJ, Bittner V, et al.; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9